Although many wrote off the biotech IPO markets as moribund earlier in 2016, the sector has been quietly issuing a steady stream of new offerings. Despite the volatility related to drug pricing, and disastrous first six-weeks of the year, we’ve recently witnessed the 24th biopharma IPO of 2016. For context, in the past two decades, other than the recent window, we’ve only seen more than two dozen VC-backed IPOs in three vintage years. In light of these metrics, and despite the negative sentiment and malaise about biotech IPOs, it’s actually been a historically very strong year in terms of new offerings.
Relative to a decade ago, those of us that have spent time finding new ways to outsmart drug-resistant bacteria have reason to feel optimistic about the current opportunities in our field.
This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.
Three newly launched companies in the Atlas portfolio raised Series A rounds.
As larger Pharma externally-enables more of its pipelines, the cadence of biotech M&A appears to be accelerating, especially for early stage deals. Another week, another biotech acquisition in the news: Allergan has acquired two private and two public R&D-stage companies in just two weeks, involving Tobira, Vitae, Akama, and Retrosense. Exciting data from PARP inhibitors and immuno-oncology programs have catalyzed hopes of a further wave of acquisitions.
Biotech M&A is all the rage these days. Allergan has acquired four small companies in the past couple weeks. Pfizer won the Medivation prize. Horizon bought rare disease play Raptor. Just to name a few. The past couple years have been some of the most active for deal-makers, underscoring the role of M&A and external sourcing as a key component of Pharma’s pipeline strategy.
This post was written by Samantha Truex, former CBO of Padlock Therapeutics, as part of the From The Trenches feature of LifeSciVC.